A Study to Compare Pharmacokinetics of GB1211

Phase 1 Completed 13 enrolled Galecto Biotech AB QPS Holdings LLC · collab

RandomizedCrossoverOpen-labelBasic science

Summary

This study is an open label, Randomized, Three-period, Crossover Study to Compare the Pharmacokinetics of GB1211 upon Dosing a Capsule under Fasting Condition and a Tablet under Fasting and Fed Conditions in Healthy Volunteers

Timeline

Start: 2023-01-03
Primary completion: 2023-04-10
Completion: 2023-04-10

Publications

Aslanis V, Abd-Elaziz K, Slack RJ, Brinch A, Gravelle L, Morley W, Phung D, Herman K, Holyer I, Poulsen KK, Dogterom P, Tantawi S, Zetterberg FR, Jacoby B, Schambye H, Lindmark B. Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1). Cancer Chemother Pharmacol. 2024 Nov;94(5):707-720. doi: 10.1007/s00280-024-04710-3. Epub 2024 Aug 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Selvigaltin	Small molecule	100 mg	Oral

Indications

No indication recorded.